

@NAME@
@ADD@
Date of birth: @DOB@

Dear @NAME@,

On @ADMITDT@, you were admitted to the University of Maryland Medical Center (UMMC) for {indicationPGx:36250}. While you were in the hospital your doctor ordered a test called *CYP2C19* Genotyping. This test can help your doctor decide which medication [e.g., clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient)] is best for you to prevent blood clots.

Your *CYP2C19* Genotyping test showed that you are expected to have a normal response to clopidogrel. In other words, you are a "**NORMAL METABOLIZER**".

OR

Your *CYP2C19* Genotyping test showed that you are expected to have decreased response to clopidogrel. In other words, you are an "**INTERMEDIATE METABOLIZER**".

OR

Your *CYP2C19* Genotyping test showed that you are expected to not respond to clopidogrel. In other words, you are a "**POOR METABOLIZER**".

OR

Your *CYP2C19* Genotyping test showed that you are expected to have a normal or increased response to clopidogrel. In other words, you are a "**RAPID METABOLIZER**".

OR

Your *CYP2C19* Genotyping test showed that you are expected to have a normal or increased response to clopidogrel. In other words, you are an "**ULTRA-RAPID METABOLIZER**".

Our Pharmacogenetics Service team is reviewing all patients who have had *CYP2C19* Genotyping. Below is some information about *CYP2C19*. We wanted you to have this information because this result can affect the choice or dosing of many medications, either now or in the future (see wallet card).

We encourage you to discuss these results with your doctors if you have any questions. **Do not change your medication without first talking to your doctor.** The PPGM Pharmacogenetics Service can be reached by phone (410-706-6140) or email (ppgm@medicine.umaryland.edu) if you have questions.

Sincerely,

The PPGM Pharmacogenetics Service and the Division of Cardiology

Mark R. Vesely, MD, FACC, FSCAI
Amber Beitelshes, Pharm.D, MPH, FAHA
Linda Jeng, MD, PhD, FACMG
Kristin Maloney, MS, MGC, CGC